SBIR/STTR Research Award

Noninvasive Home Assessment of Cardiac Filling Pressure to Identify Heart Failure Patients at High Risk for Readmission

Award identifier 734d78f3b6c082be79f2a0037ea1d41044a5eecf1db7afb782b81dd3cb2419a2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$145,709

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Vixiar Medical, Inc
Proposal award date
2017-09-01
Contract end date
2019-03-31
UEI
NEJREN5KEXT4
Solicitation number
PA16-303
Topic code
NHLBI

Research abstract

Congestive heart failure CHF is the most common reason for hospitalization in the U S with over million admissions per year Patients admitted with CHF usually need IV diuretics to promote fluid removal The readmission rate is high over by days and by days post discharge This also presents an enormous economic burden hospitalizations account for a large percentage of the $ billion spent yearly on heart failure One of the reasons for the high readmission rate is that it can be very challenging to detect elevated cardiac filling pressure until symptoms recur that prompt a return to the hospital There is much enthusiasm for the potential of remote noninvasive monitoring to predict and reduce heart failure readmissions but daily weights vital signs and symptoms have limited sensitivity and specificity or are later indicators We have developed the first device for assessing cardiac filling pressure noninvasively that can be used at home It records finger photoplethysmography ppg continuously while also guiding and recording a standardized Valsalva maneuver into an expiratory pressure transducer The latest prototype is hand held battery powered and communicates wirelessly with an iPad capable of remote transmission The device is easy to use employs technology that is robust and inexpensive and testing takes only minutes We have shown that the output measure correlates with the invasive gold standard measures of left heart filling pressure left ventricular end diastolic pressure LVEDP and pulmonary capillary wedge pressure PCWP More importantly we have shown that it identifies clinically meaningful categories of elevated LVEDP and PCWP Most recently we have shown that LVEDP derived from the device on the day of discharge has high specificity for predicting heart failure readmission need for outpatient IV diuresis or death within days after discharge Sensitivity and specificity for predicting readmission may be improved by following LVEDP over time at home In this Fast Track project we intend in Phase I to develop further the automated waveform analysis algorithms remote transmission capabilities and prototyping necessary to conduct a home based observational clinical study In the clinical study in Phase II post discharge heart failure patients will test themselves at home twice a day for up to days and the data will be transmitted remotely We will determine if LVEDP obtained twice daily predicts heart failure events a combination of heart failure readmission need for outpatient IV diuresis or death within days after discharge Our team has extensive combined expertise in waveform analysis software development medical device prototyping project engineering heart failure clinical investigation and prior success in medical device start ups If the outcome of our observational clinical study is successful the next step would be to conduct a multi center interventional trial to determine if guiding therapy based on daily device testing reduces post discharge heart failure events The device has the potential to improve quality of life reduce health care costs and improve survival in patients with heart failure Congestive heart failure is the most common reason for hospitalization and the readmission rate is high which is a substantial health and cost burden We have developed a noninvasive test for detecting congestion before symptoms develop that may reduce re hospitalizations reduce health care cost and improve quality of life in patients with heart failure We will determine in patients testing themselves each day at home after a hospital discharge how well the device predicts readmissions for heart failure

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $1,317,639. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.